-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
A cytokine signal in certain breast cancer stem cells not only serves as a diagnostic tool for HER2-negative tumors, but also provides an effective therapeutic target.
a study by Dr. Karolina Palucka, a professor at the Jackson Laboratory (JAK), and researchers at the Baylor Institute for Immunology, found that inflammation driven by IL1b (a member of the cytokine family of leptin 1) is commonly found in breast tumors, which may be an IL1 signal in metastatic breast cancer in women with HER2-negative.
"We found that IL1b in breast cancer promotes cancer-promoting inflammation. Palucka said. This is associated with poor clinical prognosmology. We found that the use of the natural IL1-subject antagonist anabinic hysteresis can effectively target this signal in the patient's body.
anabinin has been widely used to treat autoimmune and autoinflation disorders, and researchers are studying its effects as an auxiliary treatment to reduce inflammation in metastatic cancers, including metastatic colorectal cancer. In the new study, 11 women with late-stage metastasis HER2-negative breast cancer were treated with antatin, and the researchers found that expression of IL1b and other related signaling factors decreased after two weeks of treatment.
then combined antatin and standard chemotherapy to treat the patient for four months. It was found that some patients had reduced pain and improved life treatment during treatment, three of whom were still alive. The study, published recently in Cancer Research, was published in the same journal by Dr. Charles A. Dinarello of the Anschutz School of Medicine at the University of Colorado, Denver, who discovered, cloned, and masted basic biological information about IL-1.
"s study represents the efforts Palucka and his colleagues have put into cancer research over the years. Dinarello wrote. While it's great to know the risks and prognosmations of a signaling path, it's important to explore targeted therapies to really benefit patients. In the case of tumor patients with IL1b signals, simply suppressing IL1 is enough, and that's what this study did. (Bio Valley)
